TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a...
According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL...
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a...
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently...
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”...
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum...
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.